Skip to main content

Table 2 Effect of IPTsc on malaria parasitaemia during the intervention period

From: Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review

  Study site Study by drug regimen No. of children Prevalence of infection (%) PE (95 % CI)
Clarke [24] Bondo SP + AQ (four-monthly) 2584 4.6 88 (86 to 90)
   Placebo 2294 39.7
Barger [25] Kollé SP + AS 91 6.6 81 (56 to 92)
   AQ + AS 97 6.2 81 (57 to 91)
   Placebo 96 34.4
Nankabirwa [26] Tororo SP 186 79.7 0.05 (−4 to 14)
   SP + AQ 200 43.3 49 (38 to 56)
   DP 198 11.7 86 (80 to 91)
   Placebo 196 84.6
Nankabirwa [27] Tororo DP (monthly) 2638a 2 94 (93 to 96)
   DP (three to five monthly) 2644a 18 54 (49 to 58)
   Placebo 2700a 38
  1. PE protective effect, No number, SP sulfadoxine-pyrimethamine, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
  2. aTotal tests